Biotech Allakos Inc. /zigman2/quotes/203639566/composite ALLK -2.11% priced its initial public offering at $18 a share, above its $15 to $17 price range. The clinical-stage company, which focuses on developing antibodies for the treatment of eosinophil and mast cell related diseases, sold 7.1 million shares to raise $127.8 million. Shares will start trading later Thursday on Nasdaq, under the ticker symbol "ALLK."
Want to see how this story relates to your watchlist?
Just add items to create a watchlist now:
- XAllakos Inc. (ALLK)